FDA Grants Fast Track Designation to BI-1808 Plus Pembrolizumab in Ovarian Cancer

Reports

2

Domains carrying it

2

First reported

7 August 2026

Latest report

7 August 2026

◆ Sectors

◆ Where

United States

◆ Timeline

1. 7 August 2026FDA Grants Fast Track Designation to BI-1808 Plus Pembrolizumab in Ovarian Canceronclive.com
2. 7 August 2026BioInvent wins FDA Fast Track for BI-1808 after encouraging ovarian cancer dataallsci.com

◆ Connected developments

Situations Wire finds semantically close to this one. Proximity, not cause.

• FDA Grants Fast Track Designation to SOTIO's SOT106 ADC for3 reports · 3 domains · 29 August 2026
• BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a ...2 reports · 2 domains · 18 August 2026
• FDA Grants Accelerated Approval to a New Breast Cancer Treatment8 reports · 7 domains · 5 September 2026
• FDA Grants Fast Track Designation to Pan-RAS Molecular Glue ERAS-0015 for Metastatic ...2 reports · 2 domains · 24 August 2026
• U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ...12 reports · 12 domains · 17 August 2026
• FDA Grants Accelerated Approval to Iberdomide Combination for Relapsed or Refractory ...3 reports · 3 domains · 13 August 2026

◆ Share

◆ Evidence

2 reports · 2 domains

• BioInvent wins FDA Fast Track for BI-1808 after encouraging ovarian cancer dataallsci.com · 7 August 2026
• FDA Grants Fast Track Designation to BI-1808 Plus Pembrolizumab in Ovarian Canceronclive.com · 7 August 2026